Chair
Member
Audit Committee Position

Graham Cooper

Graham Cooper has served as a member of our board of directors since October 2017. From March 2018-September 2019, Mr. Cooper served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences. Previously, Mr. Cooper was the Chief Financial Officer of Receptos, Inc. from February 2013 until its sale to Celgene in August 2015 and Chief Financial Officer and Executive Vice President of finance and business development at Geron Corporation from January 2012 to December 2012. Prior to that, Mr. Cooper served as the Chief Financial Officer of Orexigen Therapeutics, Inc. and held several positions at Deutsche Bank Securities, including director, Health Care Investment Banking. Mr. Cooper also worked as an accountant at Deloitte & Touche LLP, where he earned his title as a certified public accountant. Mr. Cooper serves as a board director for Unity Biotechnology and Bioniz Therapeutics, and previously was a member of the board of directors of Celladon Corporation. Mr. Cooper received a Bachelor of Arts degree in Economics from the University of California at Berkeley and a Master of Business Administration degree from the Stanford Graduate School of Business.

Chair

Franklin M. Berger, CFA

Franklin M. Berger, CFA, has served as a member of our board of directors since November 2016. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Before that, he served at J.P. Morgan Securities, most recently as the Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Five Prime Therapeutics, Inc. since October 2014, Immune Design Corp. since March 2014, Bellus Health, Inc. since May 2010, ESSA Pharma, Inc. since March 2015, and Proteostasis Therapeutics, Inc. since February 2016. Mr. Berger previously served as a member of the board of directors BioTime, Inc. and Seattle Genetics, Inc., both publicly held biotechnology companies. Mr. Berger received a Bachelor of Arts in International Relations and a Master of Arts degree in International Economics from Johns Hopkins University, and a Master of Business Administration degree from the Harvard Business School.

Member

Michael Kauffman, M.D., Ph.D

Michael Kauffman, M.D., Ph.D., has served as a member of our board of directors since December 2016. Dr. Kauffman co-founded Karyopharm Therapeutics, Inc. in 2008 and has served as its Chief Executive Officer since January 2011 and as a member of its board of directors since 2008. Dr. Kauffman also served as the President of Karyopharm Therapeutics, Inc. from January 2011 to December 2013 and as its chief medical officer from December 2012 to December 2013. Prior to that, Dr. Kauffman served as the chief medical officer at Onyx, and as Chief Medical Officer of Proteolix, Inc. Dr. Kauffman also served as President and Chief Executive Officer of both Epix Pharmaceuticals, Inc. and Predix Pharmaceuticals, Inc., and was an operating partner at Bessemer Venture Partners. Dr. Kauffman also held several senior positions at Millennium Pharmaceuticals, Inc. and Biogen Idec, Inc. Dr. Kauffman has served on the board of directors of Verastem Inc., a publicly held biopharmaceutical company, since November 2012. Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College and his Doctor of Medicine and Doctor of Philosophy degrees in Immunology from Johns Hopkins Medical School.

Member

Audit Committee Charter

Download
Compensation Committee Position

Michael Kauffman, M.D., Ph.D

Michael Kauffman, M.D., Ph.D., has served as a member of our board of directors since December 2016. Dr. Kauffman co-founded Karyopharm Therapeutics, Inc. in 2008 and has served as its Chief Executive Officer since January 2011 and as a member of its board of directors since 2008. Dr. Kauffman also served as the President of Karyopharm Therapeutics, Inc. from January 2011 to December 2013 and as its chief medical officer from December 2012 to December 2013. Prior to that, Dr. Kauffman served as the chief medical officer at Onyx, and as Chief Medical Officer of Proteolix, Inc. Dr. Kauffman also served as President and Chief Executive Officer of both Epix Pharmaceuticals, Inc. and Predix Pharmaceuticals, Inc., and was an operating partner at Bessemer Venture Partners. Dr. Kauffman also held several senior positions at Millennium Pharmaceuticals, Inc. and Biogen Idec, Inc. Dr. Kauffman has served on the board of directors of Verastem Inc., a publicly held biopharmaceutical company, since November 2012. Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College and his Doctor of Medicine and Doctor of Philosophy degrees in Immunology from Johns Hopkins Medical School.

Chair

Graham Cooper

Graham Cooper has served as a member of our board of directors since October 2017. From March 2018-September 2019, Mr. Cooper served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences. Previously, Mr. Cooper was the Chief Financial Officer of Receptos, Inc. from February 2013 until its sale to Celgene in August 2015 and Chief Financial Officer and Executive Vice President of finance and business development at Geron Corporation from January 2012 to December 2012. Prior to that, Mr. Cooper served as the Chief Financial Officer of Orexigen Therapeutics, Inc. and held several positions at Deutsche Bank Securities, including director, Health Care Investment Banking. Mr. Cooper also worked as an accountant at Deloitte & Touche LLP, where he earned his title as a certified public accountant. Mr. Cooper serves as a board director for Unity Biotechnology and Bioniz Therapeutics, and previously was a member of the board of directors of Celladon Corporation. Mr. Cooper received a Bachelor of Arts degree in Economics from the University of California at Berkeley and a Master of Business Administration degree from the Stanford Graduate School of Business.

Member

Jean-Pierre Sommadossi, Ph.D.

Jean-Pierre Sommadossi, Ph.D., has served as a member of our board of directors since June 2015. Dr. Sommadossi has served as the founder, Chief Executive Officer and Chairman of Atea Pharmaceuticals, Inc. since December 2013. Prior to that, he co-founded Pharmasset, Inc. and held several roles at Idenix Pharmaceuticals, Inc., including Principal Founder and Chief Executive Officer and Chairman. Dr. Sommadossi serves as the Vice-Chair of the Board of Directors of Rafael Pharmaceuticals, Inc., a privately held therapeutics company. He is also a member of the Harvard Medical School Discovery Counsel and a Senior Advisor to PureTech Ventures. Dr. Sommadossi received his Doctor of Philosophy and Doctor of Pharmacy degrees from the University of Marseilles in France.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Franklin M. Berger, CFA

Franklin M. Berger, CFA, has served as a member of our board of directors since November 2016. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Before that, he served at J.P. Morgan Securities, most recently as the Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Five Prime Therapeutics, Inc. since October 2014, Immune Design Corp. since March 2014, Bellus Health, Inc. since May 2010, ESSA Pharma, Inc. since March 2015, and Proteostasis Therapeutics, Inc. since February 2016. Mr. Berger previously served as a member of the board of directors BioTime, Inc. and Seattle Genetics, Inc., both publicly held biotechnology companies. Mr. Berger received a Bachelor of Arts in International Relations and a Master of Arts degree in International Economics from Johns Hopkins University, and a Master of Business Administration degree from the Harvard Business School.

Chair

Jason R. Dinges, Ph.D., J.D

Jason R. Dinges, Ph.D., J.D., has served as a member of our board of directors since April 2018. Since February 2011, Dr. Dinges has served as an Investment Advisor at Morningside Technology Advisory LLC. Before that, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s chemical, biotechnology, and pharmaceutical practice group. Dr. Dinges also serves on the board of directors of various privately-held biotechnology companies. Dr. Dinges received his Doctor of Philosophy in Genetics from Iowa State University and a Doctor of Laws degree from the University of Iowa College of Law.

Member

Jean-Pierre Sommadossi, Ph.D.

Jean-Pierre Sommadossi, Ph.D., has served as a member of our board of directors since June 2015. Dr. Sommadossi has served as the founder, Chief Executive Officer and Chairman of Atea Pharmaceuticals, Inc. since December 2013. Prior to that, he co-founded Pharmasset, Inc. and held several roles at Idenix Pharmaceuticals, Inc., including Principal Founder and Chief Executive Officer and Chairman. Dr. Sommadossi serves as the Vice-Chair of the Board of Directors of Rafael Pharmaceuticals, Inc., a privately held therapeutics company. He is also a member of the Harvard Medical School Discovery Counsel and a Senior Advisor to PureTech Ventures. Dr. Sommadossi received his Doctor of Philosophy and Doctor of Pharmacy degrees from the University of Marseilles in France.

Member

Nominating and Corporate Governance Committee Charter

Download

Graham Cooper

Graham Cooper has served as a member of our board of directors since October 2017. From March 2018-September 2019, Mr. Cooper served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences. Previously, Mr. Cooper was the Chief Financial Officer of Receptos, Inc. from February 2013 until its sale to Celgene in August 2015 and Chief Financial Officer and Executive Vice President of finance and business development at Geron Corporation from January 2012 to December 2012. Prior to that, Mr. Cooper served as the Chief Financial Officer of Orexigen Therapeutics, Inc. and held several positions at Deutsche Bank Securities, including director, Health Care Investment Banking. Mr. Cooper also worked as an accountant at Deloitte & Touche LLP, where he earned his title as a certified public accountant. Mr. Cooper serves as a board director for Unity Biotechnology and Bioniz Therapeutics, and previously was a member of the board of directors of Celladon Corporation. Mr. Cooper received a Bachelor of Arts degree in Economics from the University of California at Berkeley and a Master of Business Administration degree from the Stanford Graduate School of Business.

Franklin M. Berger, CFA

Franklin M. Berger, CFA, has served as a member of our board of directors since November 2016. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Before that, he served at J.P. Morgan Securities, most recently as the Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Five Prime Therapeutics, Inc. since October 2014, Immune Design Corp. since March 2014, Bellus Health, Inc. since May 2010, ESSA Pharma, Inc. since March 2015, and Proteostasis Therapeutics, Inc. since February 2016. Mr. Berger previously served as a member of the board of directors BioTime, Inc. and Seattle Genetics, Inc., both publicly held biotechnology companies. Mr. Berger received a Bachelor of Arts in International Relations and a Master of Arts degree in International Economics from Johns Hopkins University, and a Master of Business Administration degree from the Harvard Business School.

Michael Kauffman, M.D., Ph.D

Michael Kauffman, M.D., Ph.D., has served as a member of our board of directors since December 2016. Dr. Kauffman co-founded Karyopharm Therapeutics, Inc. in 2008 and has served as its Chief Executive Officer since January 2011 and as a member of its board of directors since 2008. Dr. Kauffman also served as the President of Karyopharm Therapeutics, Inc. from January 2011 to December 2013 and as its chief medical officer from December 2012 to December 2013. Prior to that, Dr. Kauffman served as the chief medical officer at Onyx, and as Chief Medical Officer of Proteolix, Inc. Dr. Kauffman also served as President and Chief Executive Officer of both Epix Pharmaceuticals, Inc. and Predix Pharmaceuticals, Inc., and was an operating partner at Bessemer Venture Partners. Dr. Kauffman also held several senior positions at Millennium Pharmaceuticals, Inc. and Biogen Idec, Inc. Dr. Kauffman has served on the board of directors of Verastem Inc., a publicly held biopharmaceutical company, since November 2012. Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College and his Doctor of Medicine and Doctor of Philosophy degrees in Immunology from Johns Hopkins Medical School.

Michael Kauffman, M.D., Ph.D

Michael Kauffman, M.D., Ph.D., has served as a member of our board of directors since December 2016. Dr. Kauffman co-founded Karyopharm Therapeutics, Inc. in 2008 and has served as its Chief Executive Officer since January 2011 and as a member of its board of directors since 2008. Dr. Kauffman also served as the President of Karyopharm Therapeutics, Inc. from January 2011 to December 2013 and as its chief medical officer from December 2012 to December 2013. Prior to that, Dr. Kauffman served as the chief medical officer at Onyx, and as Chief Medical Officer of Proteolix, Inc. Dr. Kauffman also served as President and Chief Executive Officer of both Epix Pharmaceuticals, Inc. and Predix Pharmaceuticals, Inc., and was an operating partner at Bessemer Venture Partners. Dr. Kauffman also held several senior positions at Millennium Pharmaceuticals, Inc. and Biogen Idec, Inc. Dr. Kauffman has served on the board of directors of Verastem Inc., a publicly held biopharmaceutical company, since November 2012. Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College and his Doctor of Medicine and Doctor of Philosophy degrees in Immunology from Johns Hopkins Medical School.

Graham Cooper

Graham Cooper has served as a member of our board of directors since October 2017. From March 2018-September 2019, Mr. Cooper served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences. Previously, Mr. Cooper was the Chief Financial Officer of Receptos, Inc. from February 2013 until its sale to Celgene in August 2015 and Chief Financial Officer and Executive Vice President of finance and business development at Geron Corporation from January 2012 to December 2012. Prior to that, Mr. Cooper served as the Chief Financial Officer of Orexigen Therapeutics, Inc. and held several positions at Deutsche Bank Securities, including director, Health Care Investment Banking. Mr. Cooper also worked as an accountant at Deloitte & Touche LLP, where he earned his title as a certified public accountant. Mr. Cooper serves as a board director for Unity Biotechnology and Bioniz Therapeutics, and previously was a member of the board of directors of Celladon Corporation. Mr. Cooper received a Bachelor of Arts degree in Economics from the University of California at Berkeley and a Master of Business Administration degree from the Stanford Graduate School of Business.

Jean-Pierre Sommadossi, Ph.D.

Jean-Pierre Sommadossi, Ph.D., has served as a member of our board of directors since June 2015. Dr. Sommadossi has served as the founder, Chief Executive Officer and Chairman of Atea Pharmaceuticals, Inc. since December 2013. Prior to that, he co-founded Pharmasset, Inc. and held several roles at Idenix Pharmaceuticals, Inc., including Principal Founder and Chief Executive Officer and Chairman. Dr. Sommadossi serves as the Vice-Chair of the Board of Directors of Rafael Pharmaceuticals, Inc., a privately held therapeutics company. He is also a member of the Harvard Medical School Discovery Counsel and a Senior Advisor to PureTech Ventures. Dr. Sommadossi received his Doctor of Philosophy and Doctor of Pharmacy degrees from the University of Marseilles in France.

Franklin M. Berger, CFA

Franklin M. Berger, CFA, has served as a member of our board of directors since November 2016. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Before that, he served at J.P. Morgan Securities, most recently as the Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Five Prime Therapeutics, Inc. since October 2014, Immune Design Corp. since March 2014, Bellus Health, Inc. since May 2010, ESSA Pharma, Inc. since March 2015, and Proteostasis Therapeutics, Inc. since February 2016. Mr. Berger previously served as a member of the board of directors BioTime, Inc. and Seattle Genetics, Inc., both publicly held biotechnology companies. Mr. Berger received a Bachelor of Arts in International Relations and a Master of Arts degree in International Economics from Johns Hopkins University, and a Master of Business Administration degree from the Harvard Business School.

Jason R. Dinges, Ph.D., J.D

Jason R. Dinges, Ph.D., J.D., has served as a member of our board of directors since April 2018. Since February 2011, Dr. Dinges has served as an Investment Advisor at Morningside Technology Advisory LLC. Before that, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s chemical, biotechnology, and pharmaceutical practice group. Dr. Dinges also serves on the board of directors of various privately-held biotechnology companies. Dr. Dinges received his Doctor of Philosophy in Genetics from Iowa State University and a Doctor of Laws degree from the University of Iowa College of Law.

Jean-Pierre Sommadossi, Ph.D.

Jean-Pierre Sommadossi, Ph.D., has served as a member of our board of directors since June 2015. Dr. Sommadossi has served as the founder, Chief Executive Officer and Chairman of Atea Pharmaceuticals, Inc. since December 2013. Prior to that, he co-founded Pharmasset, Inc. and held several roles at Idenix Pharmaceuticals, Inc., including Principal Founder and Chief Executive Officer and Chairman. Dr. Sommadossi serves as the Vice-Chair of the Board of Directors of Rafael Pharmaceuticals, Inc., a privately held therapeutics company. He is also a member of the Harvard Medical School Discovery Counsel and a Senior Advisor to PureTech Ventures. Dr. Sommadossi received his Doctor of Philosophy and Doctor of Pharmacy degrees from the University of Marseilles in France.